AstraZeneca weathers the stock market vaccine crisis with the sector far from highs

AstraZeneca manages to circumvent the effects of the crisis around the Covid-19 vaccine that it has developed together with the University of Oxford on the stock market. Shares of the British pharmaceutical company advance around 2.5% in London and recover the 7,270 pounds (around 8,418 euros) after the European Medicines Agency (EMA) confirmed last night a “possible link” with the cases of blood clots reported in some of the people who have been inoculated with it, but it had an impact in that the benefits of its use outweigh the risks, which are very “rare” and “unusual”.

The company, as it happens with the rest of the big pharmaceutical companies that have developed a vaccine against the virus, cIt is currently almost 17% below the highs it reached at the beginning of last November. (He reached 8,785 pounds per title). Then, the market resuscitated due to expectations from the lethargy in which the Covid-19 crisis had plunged them thanks to the results of the Pfizer-BioNTech and Moderna candidates.

The shares of pharmaceutical companies in general heated up in the final stretch of last year as the light was already glimpsing at the end of the tunnel of the health and economic crisis and gave a warm welcome to the pioneering messenger RNA technique that has revolutionized medicine. It can be said that since then the German and the American companies have eclipsed the rest of the companies. And also since then AstraZeneca has accumulated a history of problems that have only increased.

Its manufacturers announced that they would default on the delivery commitment of the doses ordered and it was made public that the company was sending vaccines to countries outside the European Union that had paid more – and this despite the fact that the 27 had advanced the firm more than 300 million to promote research – and that the United Kingdom was acquiring doses massively. The side effects in some of the people who were inoculated ended up leading more than half of Europe to suspend their vaccination.

See also  Mattarella's flair for Moderna - Il Tempo

Spain, which had taken it up again, has decided to stop applying it to those under 60 years of age. Our country has acquired more than 12.23 million doses of the vaccine, of which only slightly more than 3.23 million have been received and delivered to the autonomous regions, and 2.15 million of these have been administered. The problem is, as they point out from Rent 4 in what mistrust grows And while Italy also joins Germany and France in recommending the vaccine for those over 60, the UK has suddenly changed its recommendation, asking that those under 30 be offered alternative vaccines.

“All this could complicate vaccination campaigns, with possible negative implications in the economic reopening,” warn its managers. Since Link Securities agree on this point of view and recall how the AstraZeneca vaccine is currently essential if the region wants to achieve the immunization goals established by the European Commission (EC) of reach the target of 70% of the vaccinated adult population by the end of the summer.

Eclipsed by Pfizer-BioNTech and Moderna

The horizon looks different for the other big names in the sector. Pfizer marked its stock market ceiling on December 8 at $ 42.56, just four days before, on Saturday 12, the United States Federal Drug Agency (DFA) gave the green light to the emergency use of the vaccine -the The same body has not come to approve the use of AstraZeneca in the country. The first doses began to be administered in the country the following Monday. Since then its price has deflated by 15.6%.

See also  WHO recalls that seasonal flu kills 60,000 people a year in Europe

After the expectations generated at the end of last year and the stock market heat, reality has prevailed and this offers a photograph of vaccination at a good pace in the United States, the United Kingdom or Israel, to give some examples, and a slower process and not without criticism in Europe. The german BioNTech, led by Uğur Şahin, is now moving 12.5% ​​below the maximum it marked on Wall Street on December 10 at $ 129.54.

A vial with the AstraZeneca vaccine, in a mass vaccination device against Covid-19, in the Palace of Exhibitions and Congresses of Santander, in Cantabria (Spain), on March 31, 2021. Cantabria begins this Wednesday a mass vaccination against the coronavirus of 2,500 people.  Specifically, between the morning and afternoon today, a total of 1,000 people belonging to essential groups and between 55 and 65 years old, as well as those who have been left out of the program for some reason, will be vaccinated with AstraZeneca.  Likewise, on Thursday, Friday and Saturday morning, up to 1,500 people over 80 will receive the vaccine, mainly from the Vargas, Centro, Puertochico, Dávila and La Marina health centers.  MARCH 31, 2021; VACCINATION; COVID-19; HEALTH; CANTABRIA; SANTANDER Juan Manuel Serrano Arce / Europa Press 3/31/2021

In the case of ModernIts historic ceiling marked it at the beginning of this year, on February 8 ($ 185.98) and since then its price has plummeted 29.3%. While Johnson & Johnson moves just 4% below the maximum of $ 170.48 that it marked on January 26. It was not until March 11 when the EU approved the use of the vaccine from its European subsidiary, Janssen in the Old Continent – its doses will arrive in Spain this week.


Leave a Comment